Literature DB >> 22505518

Kallikrein 6 is a novel molecular trigger of reactive astrogliosis.

Isobel A Scarisbrick1, Maja Radulovic, Joshua E Burda, Nadya Larson, Sachiko I Blaber, Caterina Giannini, Michael Blaber, Alexander G Vandell.   

Abstract

Kallikrein-related peptidase 6 (KLK6) is a trypsin-like serine protease upregulated at sites of central nervous system (CNS) injury, including de novo expression by reactive astrocytes, yet its physiological actions are largely undefined. Taken with recent evidence that KLK6 activates G-protein-coupled protease-activated receptors (PARs), we hypothesized that injury-induced elevations in KLK6 contribute to the development of astrogliosis and that this occurs in a PAR-dependent fashion. Using primary murine astrocytes and the Neu7 astrocyte cell line, we show that KLK6 causes astrocytes to transform from an epitheliod to a stellate morphology and to secrete interleukin 6 (IL-6). By contrast, KLK6 reduced expression of glial fibrillary acidic protein (GFAP). The stellation-promoting activities of KLK6 were shown to be dependent on activation of the thrombin receptor, PAR1, as a PAR1-specific inhibitor, SCH79797, blocked KLK6-induced morphological changes. The ability of KLK6 to promote astrocyte stellation was also shown to be linked to activation of protein kinase C (PKC). These studies indicate that KLK6 is positioned to serve as a molecular trigger of select physiological processes involved in the development of astrogliosis and that this is likely to occur at least in part by activation of the G-protein-coupled receptor, PAR1.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22505518      PMCID: PMC3335747          DOI: 10.1515/hsz-2011-0241

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  84 in total

1.  Astrocytes in culture express fibrillar collagen.

Authors:  Nicolas Heck; Jeremy Garwood; Katrin Schütte; James Fawcett; Andreas Faissner
Journal:  Glia       Date:  2003-03       Impact factor: 7.452

2.  Enzymatic properties of rat myelencephalon-specific protease.

Authors:  Sachiko I Blaber; Isobel A Scarisbrick; Matthew J Bernett; Pushparani Dhanarajan; Margaret A Seavy; Yonghao Jin; Martin A Schwartz; Moses Rodriguez; Michael Blaber
Journal:  Biochemistry       Date:  2002-01-29       Impact factor: 3.162

3.  Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system.

Authors:  Matthew J Bernett; Sachiko I Blaber; Isobel A Scarisbrick; Pushparani Dhanarajan; Steven M Thompson; Michael Blaber
Journal:  J Biol Chem       Date:  2002-04-30       Impact factor: 5.157

4.  Thrombin (PAR-1)-induced proliferation in astrocytes via MAPK involves multiple signaling pathways.

Authors:  Hong Wang; Joachim J Ubl; Rolf Stricker; Georg Reiser
Journal:  Am J Physiol Cell Physiol       Date:  2002-11       Impact factor: 4.249

5.  Activity of a newly identified serine protease in CNS demyelination.

Authors:  I A Scarisbrick; S I Blaber; C F Lucchinetti; C P Genain; M Blaber; M Rodriguez
Journal:  Brain       Date:  2002-06       Impact factor: 13.501

6.  Up-regulation of proteinase-activated receptor 1 expression in astrocytes during HIV encephalitis.

Authors:  Leonie A Boven; Nathalie Vergnolle; Scot D Henry; Claudia Silva; Yoshinori Imai; Janet Holden; Kenneth Warren; Morley D Hollenberg; Christopher Power
Journal:  J Immunol       Date:  2003-03-01       Impact factor: 5.422

7.  Decreased concentration of human kallikrein 6 in brain extracts of Alzheimer's disease patients.

Authors:  Maryam Zarghooni; Antoninus Soosaipillai; Linda Grass; Andreas Scorilas; Nader Mirazimi; Eleftherios P Diamandis
Journal:  Clin Biochem       Date:  2002-05       Impact factor: 3.281

8.  A role for hypertrophic astrocytes and astrocyte precursors in a case of rapidly progressive multiple sclerosis.

Authors:  Yvette Morcos; Sang Min Lee; Michael C Levin
Journal:  Mult Scler       Date:  2003-08       Impact factor: 6.312

9.  Astrocyte characterization in the multiple sclerosis glial scar.

Authors:  J E Holley; D Gveric; J Newcombe; M L Cuzner; N J Gutowski
Journal:  Neuropathol Appl Neurobiol       Date:  2003-10       Impact factor: 8.090

Review 10.  GFAP: functional implications gleaned from studies of genetically engineered mice.

Authors:  Albee Messing; Michael Brenner
Journal:  Glia       Date:  2003-07       Impact factor: 8.073

View more
  29 in total

Review 1.  Kallikreins - The melting pot of activity and function.

Authors:  Magdalena Kalinska; Ulf Meyer-Hoffert; Tomasz Kantyka; Jan Potempa
Journal:  Biochimie       Date:  2015-09-25       Impact factor: 4.079

Review 2.  Astrocytes, therapeutic targets for neuroprotection and neurorestoration in ischemic stroke.

Authors:  Zhongwu Liu; Michael Chopp
Journal:  Prog Neurobiol       Date:  2015-10-09       Impact factor: 11.685

3.  Genetic targeting of protease activated receptor 2 reduces inflammatory astrogliosis and improves recovery of function after spinal cord injury.

Authors:  Maja Radulovic; Hyesook Yoon; Jianmin Wu; Karim Mustafa; Michael G Fehlings; Isobel A Scarisbrick
Journal:  Neurobiol Dis       Date:  2015-08-24       Impact factor: 5.996

4.  Differential expression of multiple kallikreins in a viral model of multiple sclerosis points to unique roles in the innate and adaptive immune response.

Authors:  Michael Panos; George P Christophi; Moses Rodriguez; Isobel A Scarisbrick
Journal:  Biol Chem       Date:  2014-09       Impact factor: 3.915

5.  Critical role for PAR1 in kallikrein 6-mediated oligodendrogliopathy.

Authors:  Joshua E Burda; Maja Radulovic; Hyesook Yoon; Isobel A Scarisbrick
Journal:  Glia       Date:  2013-07-08       Impact factor: 7.452

6.  Kallikrein cascades in traumatic spinal cord injury: in vitro evidence for roles in axonopathy and neuron degeneration.

Authors:  Maja Radulovic; Hyesook Yoon; Nadya Larson; Jianmin Wu; Rachel Linbo; Joshua E Burda; Eleftherios P Diamandis; Sachiko I Blaber; Michael Blaber; Michael G Fehlings; Isobel A Scarisbrick
Journal:  J Neuropathol Exp Neurol       Date:  2013-11       Impact factor: 3.685

Review 7.  Unleashing the therapeutic potential of human kallikrein-related serine proteases.

Authors:  Ioannis Prassas; Azza Eissa; Gennadiy Poda; Eleftherios P Diamandis
Journal:  Nat Rev Drug Discov       Date:  2015-02-20       Impact factor: 84.694

Review 8.  What have we learned about the kallikrein-kinin and renin-angiotensin systems in neurological disorders?

Authors:  Maria da Graça Naffah-Mazzacoratti; Telma Luciana Furtado Gouveia; Priscila Santos Rodrigues Simões; Sandra Regina Perosa
Journal:  World J Biol Chem       Date:  2014-05-26

9.  The thrombin receptor is a critical extracellular switch controlling myelination.

Authors:  Hyesook Yoon; Maja Radulovic; Kristen L Drucker; Jianmin Wu; Isobel A Scarisbrick
Journal:  Glia       Date:  2015-01-27       Impact factor: 7.452

10.  Kallikrein-related peptidase-6 (KLK6) mRNA expression is an independent prognostic tissue biomarker of poor disease-free and overall survival in colorectal adenocarcinoma.

Authors:  Spyridon Christodoulou; Dimitra K Alexopoulou; Christos K Kontos; Andreas Scorilas; Iordanis N Papadopoulos
Journal:  Tumour Biol       Date:  2014-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.